Physician profile
Ren Zhang
NPI 1114909181
$12,854.25
in general payments reported to CMS, 2019-2025
29 companies · $823 in 2025
The $823 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,967 · 2020: $646 · 2021: $709 · 2022: $728 · 2023: $3,103 · 2024: $2,879 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Travel and Lodging: $2,746 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.94 |
| Travel and Lodging | $2,745.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,648.15 | 2019-2025 | Watchman Access System, Watchman Flx |
| Heartflow, INC. | $1,981.61 | 2019-2025 | Ffrct |
| Abbott Laboratories | $1,643.05 | 2019-2024 | Jeti Peripheral Catheter, Amplatzer Amulet, Cardiomems |
| Siemens Medical Solutions USA, INC. | $1,061.91 | 2023 | Acuson Sc2000 Diagnostic Ultrasound System |
| Fujifilm Healthcare Americas Corporation | $823.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $722.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $676.14 | 2019-2025 | Farxiga, Wainua |
| Amgen INC. | $495.63 | 2019-2025 | Repatha |
| Cleerly, INC. | $457.17 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Janssen Pharmaceuticals, INC | $415.29 | 2019-2022 | |
| Edwards Lifesciences Corporation | $336.84 | 2019-2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $220.50 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $219.83 | 2019-2022 | |
| Amarin Pharma, INC. | $168.90 | 2019-2022 | |
| Medtronic, INC. | $154.05 | 2023 | Signia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $120.77 | 2019-2022 | |
| United Therapeutics Corporation | $116.54 | 2019 | |
| Ge Healthcare | $96.93 | 2019 | |
| Cathworks, INC. | $92.81 | 2023 | Ffrangio |
| Merck Sharp & Dohme LLC | $81.91 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $79.46 | 2019-2022 | |
| Medtronic Vascular, INC. | $71.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $47.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $38.98 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.82 | 2025 | Jardiance |
| Braemar Manufacturing, LLC | $20.57 | 2019 | |
| Covidien LP | $14.00 | 2019 | |
| Cook Medical LLC | $11.36 | 2019 | |
| Cvrx, INC. | $7.43 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ren Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.